Abstract | PURPOSE: METHODS: RESULTS: Mean patient age was 66.3 +/- 14.9 years (range 33.5-89.3 years). The mean time to apraclonidine allergy from initial exposure was 12.9 +/- 12.9 months (range 2.1-46.8 months). For the 10 patients rechallenged with apraclonidine, the mean time to allergy was 13.6 +/- 10.2 days (range 3-32 days). Mean duration of brimonidine therapy was 140.7 +/- 66.2 days (range 14-286 days), with 11 patients reaching at least 150 days of follow-up. Two patients developed symptomatic brimonidine allergy at 138 and 201 days respectively. For those patients who did not develop symptoms of allergy to brimonidine, there was no significant change in any of the parameters by which allergy was graded throughout the study. CONCLUSIONS: Patients with known apraclonidine allergy do not develop an early allergic response to brimonidine. These data rule against a cross-reactive allergic response between these two alpha 2-adrenoreceptor agonists.
|
Authors | R N Gordon, J M Liebmann, D S Greenfield, P Lama, R Ritch |
Journal | Eye (London, England)
(Eye (Lond))
Vol. 12 ( Pt 4)
Pg. 697-700
( 1998)
ISSN: 0950-222X [Print] England |
PMID | 9850267
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adrenergic alpha-Agonists
- Antihypertensive Agents
- Quinoxalines
- Brimonidine Tartrate
- apraclonidine
- Clonidine
|
Topics |
- Adrenergic alpha-Agonists
(adverse effects)
- Adult
- Aged
- Aged, 80 and over
- Antihypertensive Agents
(adverse effects)
- Brimonidine Tartrate
- Clonidine
(adverse effects, analogs & derivatives)
- Cross Reactions
- Drug Hypersensitivity
(etiology)
- Eye Diseases
(chemically induced)
- Follow-Up Studies
- Glaucoma
(drug therapy)
- Humans
- Middle Aged
- Quinoxalines
(adverse effects)
- Time Factors
|